Trial reportFrontiers in nutrition2026
Daily consumption of sulfate- and magnesium-rich mineral water enhances bowel function in adults with chronic constipation: a randomized double-blind real-world trial.
Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Functional constipation is one of the most common disorders of gut-brain interaction. Adequate hydration is recommended as first-line therapy, yet evidence regarding the efficacy of sulfate- and magnesium-rich mineral water remains limited. Therefore, this study investigated its efficacy and safety in a nationwide decentralized randomized controlled trial. Methods: In this randomized, double-blind, controlled parallel-group trial, adults with chronic constipation according to the Rome IV criteria consumed either 1 L/day of sulfate- and magnesium-rich mineral water (HSM) or a low-mineralized control water (LSM) for 3 weeks following a one-week run-in period. Participants maintained a total daily fluid intake of at least 1,5L/day. The primary outcome was the change in weekly bowel movement frequency after 3 weeks. Additional analyses were conducted after 2 weeks of intervention. Secondary outcomes included stool consistency, responder rates, time to treatment response, constipation-related symptoms (PAC-SYM), constipation-related quality of life (PAC-QoL), gastrointestinal transit time, laxative use, and safety. Results: After 2 weeks (additional analysis), bowel movement frequency increased significantly more in the HSM group than in the control group (mean change: 1.31 ± 3.24 vs. 0.34 ± 2.49 bowel movements/week; Discussion: Daily consumption of 1 L of sulfate- and magnesium-rich mineral water, combined with adequate hydration, improved bowel movement frequency at week two and accelerated treatment response in adults with chronic constipation, whereas the between-group difference at the registered primary endpoint (week three) was not statistically significant. These findings suggest that sulfate- and magnesium-rich mineral water may serve as a safe, non-pharmacological dietary approach for the management of chronic constipation under real-world conditions. Clinical trial registration: https://clinicaltrials.gov/, DRKS00034871.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.